The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
Open accessAbstract
Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory depression. Accordingly, there is a longstanding interest in the development of new opioid analgesics with improved therapeutic profiles. The alkaloids of the Southeast Asian plant Mitragyna speciosa, represented by the prototypical member mitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological properties. Here we describe the first receptor-level functional characterization of mitragynine and related natural alkaloids at the human mu-, kappa-, and delta-opioid receptors. These results show that mitragynine and the oxidized analogue 7-hydroxymitragynine, are partial agonists of the human mu-opioid receptor and competitive antagonists at the kappa- and delta-opioid receptors. We also show that mitragynine and 7-hydroxymitragynine are G-protein-biased agonists of the mu-opioid receptor, which do not recruit β-arrestin following receptor activation. Therefore, the Mitragyna alkaloid scaffold represents a novel framework for the development of functionally biased opioid modulators, which may exhibit improved therapeutic profiles. Also presented is an enantioselective total synthesis of both (-)-mitragynine and its unnatural enantiomer, (+)-mitragynine, employing a proline-catalyzed Mannich-Michael reaction sequence as the key transformation. Pharmacological evaluation of (+)-mitragynine revealed its much weaker opioid activity. Likewise, the intermediates and chemical transformations developed in the total synthesis allowed the elucidation of previously unexplored structure-activity relationships (SAR) within the Mitragyna scaffold. Molecular docking studies, in combination with the observed chemical SAR, suggest that Mitragyna alkaloids adopt a binding pose at the mu-opioid receptor that is distinct from that of classical opioids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Ballesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Crystal structure of the µ-opioid receptor bound to a morphinan antagonist
Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., & Granier, S. (2012) · Nature · doi:10.1038/nature10954 · Cited by 1,356
Structural insights into µ-opioid receptor activation
Huang, W., Manglik, A., Venkatakrishnan, A. J., Laeremans, T., Feinberg, E. N., Sanborn, A. L., Kato, H. E., Livingston, K. E., Thorsen, T. S., Kling, R. C., et al. (2015) · Nature · doi:10.1038/nature14886 · Cited by 885
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin κ-Opioid System
Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., & Chavkin, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4458-07.2008 · Cited by 601
Mu Opioids and Their Receptors: Evolution of a Concept
Pasternak, G. W., & Pan, Y.-X. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007138 · Cited by 578
Clinical Pharmacology of Opioids for Pain
Inturrisi, C. E. (2002) · The Clinical Journal of Pain · doi:10.1097/00002508-200207001-00002 · Cited by 571
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485
Dreamland: The True Tale of America's Opiate Epidemic
Quinones, S. (2015) · Cited by 374
Takayama, H. (2004) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.52.916 · Cited by 356
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Self‐treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)
Boyer, E. W., Babu, K. M., Adkins, J. E., McCurdy, C. R., & Halpern, J. H. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02209.x · Cited by 343
Takayama, H., Ishikawa, H., Kurihara, M., Kitajima, M., Aimi, N., Ponglux, D., Koyama, F., Matsumoto, K., Moriyama, T., Yamamoto, L. T., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010576e · Cited by 273
Soergel, D. G., Subach, R. A., Burnham, N., Lark, M. W., James, I. E., Sadler, B. M., Skobieranda, F., Violin, J. D., & Webster, L. R. (2014) · Pain · doi:10.1016/j.pain.2014.06.011 · Cited by 262
Raehal, K. M., Schmid, C. L., Groer, C. E., & Bohn, L. M. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004598 · Cited by 256
Matsumoto, K., Horie, S., Ishikawa, H., Takayama, H., Aimi, N., Ponglux, D., & Watanabe, K. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.054 · Cited by 228
Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., & Bohn, L. M. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.028258 · Cited by 224
Zhan, X., Gimenez, L. E., Gurevich, V. V., & Spiller, B. W. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.12.034 · Cited by 220
kappa-Opioid receptor signaling and brain reward function
Bruijnzeel, A. W. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.09.008 · Cited by 214
The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist
Gassaway, M. M., Rives, M.-L., Kruegel, A. C., Javitch, J. A., & Sames, D. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.30 · Cited by 195
Self-citationMatsumoto, K., Mizowaki, M., Suchitra, T., Murakami, Y., Takayama, H., Sakai, S.-I., Aimi, N., & Watanabe, H. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00714-5 · Cited by 195
Rekas, A., Alattia, J.-R., Nagai, T., Miyawaki, A., & Ikura, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209524200 · Cited by 193
Karp, J. F., Butters, M. A., Begley, A. E., Miller, M. D., Lenze, E. J., Blumberger, D. M., Mulsant, B. H., & Reynolds, C. F. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08725 · Cited by 191
Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism
Luttrell, L. M., Maudsley, S., & Bohn, L. M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099630 · Cited by 190
Farah Idayu, N., Taufik Hidayat, M., Moklas, M. A. M., Sharida, F., Nurul Raudzah, A. R., Shamima, A. R., & Apryani, E. (2011) · Phytomedicine · doi:10.1016/j.phymed.2010.08.011 · Cited by 169
Crystal Structures of the Luciferase and Green Fluorescent Protein from Renilla reniformis
Loening, A. M., Fenn, T. D., & Gambhir, S. S. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.09.078 · Cited by 163
Ligand‐directed signalling within the opioid receptor family
Pradhan, A. A. A., Smith, M. L., Kieffer, B. L., & Evans, C. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02075.x · Cited by 156
β-Endorphin: Intravenous Infusion Causes Behavioral Change in Psychiatric Inpatients
Gerner, R. H. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780190040005 · Cited by 154
Possible antidepressive effects of opioids: Action of buprenorphine
Emrich, H. M., Vogt, P., & Herz, A. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb39483.x · Cited by 152
Rojas-Corrales, M. O., Berrocoso, E., Gibert‐Rahola, J., & Micó, J. A. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02220-8 · Cited by 110
Treatment Augmentation With Opiates in Severe and Refractory Major Depression
Stoll, A. L., & Rueter, S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.2017 · Cited by 102
Tramadol induces antidepressant-type effects in mice
Rojas-Corrales, M. O., Gibert‐Rahola, J., & Micó, J. A. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00369-5 · Cited by 93
Shapira, N. A., Keck, P. E., Goldsmith, T. D., McConville, B. J., Eis, M., & McElroy, S. L. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)6:4<170::aid-da7>3.0.co;2-g · Cited by 87
Dean, A. J., Bell, J., Christie, M. J., & Mattick, R. P. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.002 · Cited by 78
Molecular Insights Into μ Opioid Pharmacology
Pasternak, G. W. (2009) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181c49d2e · Cited by 73
Antagonists of the kappa opioid receptor
Urbano, M., Guerrero, M. A., Rosen, H., & Roberts, E. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.040 · Cited by 69
Lamb, K. R., Tidgewell, K. J., Simpson, D. S., Bohn, L., & Prisinzano, T. E. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.026 · Cited by 63
Largent‐Milnes, T. M., Yamamoto, T., Nair, P., Moulton, J., Hruby, V. J., Lai, J., Porreca, F., & Vanderah, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00824.x · Cited by 59
Effects of morphine, naloxone and their interaction in the learned-helplessness paradigm in rats
Besson, A., Privat, A. M., Fialip, J., & Eschalier, A. (1996) · Psychopharmacology · doi:10.1007/bf02246283 · Cited by 52
Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice
Fichna, J., Janecka, A. E., Piestrzeniewicz, M. K., Costentin, J., & do-Rego, J.-C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301149 · Cited by 51
Clayton, C. C., Donthamsetti, P., Lambert, N. A., Javitch, J. A., & Neve, K. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.605378 · Cited by 50
Self-citationTreatment of Refractory Major Depression With Tramadol Monotherapy
Shapira, N. A., Verduin, M. L., & DeGraw, J. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0312b · Cited by 50
Orally Active Opioid Compounds from a Non-Poppy Source
Raffa, R. B., Beckett, J. R., Brahmbhatt, V. N., Ebinger, T. M., Fabian, C. A., Nixon, J. R., Orlando, S. T., Rana, C., Tejani, A. H., & Tomazic, R. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400143z · Cited by 47
Stevenson, G. W., Luginbuhl, A., Dunbar, C., LaVigne, J. E., Dutra, J., Atherton, P., Bell, B. E., Cone, K., Giuvelis, D., Polt, R. L., et al. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.022 · Cited by 29
Grinnell, S. G., Majumdar, S., Narayan, A., Rouzic, V. L., Ansonoff, M. A., Pintar, J. E., & Pasternak, G. W. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213199 · Cited by 26
Self-citationResearch and Development of Opioid-Related Ligands
Ko, M., & Husbands, S. M. (2013) · ACS symposium series · doi:10.1021/bk-2013-1131 · Cited by 25
Cited by
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
“While no calculation of the degree of bias that each of these individual compounds possess was provided, promising results were obtained showing that they could induce antinociception with fewer side effects in mice (Kruegel et al., 2016; Manglik et al., 2016).”
Patterns of Kratom use and health impact in the US—Results from an online survey
Grundmann, O. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.007 · Cited by 309
Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Luo, M.-L., Zhao, Q., He, X.-H., Xie, X., Zhu, H.-P., You, F.-M., Peng, C., Zhan, G., & Huang, W. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114574 · Cited by 25
Retracted
Metadata
- Authors
- Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sames, D.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-05-18
- Volume
- 138
- Issue
- 21
- Pages
- 6754-6764
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2398657959
- Cited by
- 325
- References
- 48
- FWCI
- 26.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.